PT2854910T - Níveis de ceramida no tratamento e prevenção de infeções - Google Patents
Níveis de ceramida no tratamento e prevenção de infeçõesInfo
- Publication number
- PT2854910T PT2854910T PT137976353T PT13797635T PT2854910T PT 2854910 T PT2854910 T PT 2854910T PT 137976353 T PT137976353 T PT 137976353T PT 13797635 T PT13797635 T PT 13797635T PT 2854910 T PT2854910 T PT 2854910T
- Authority
- PT
- Portugal
- Prior art keywords
- infections
- prevention
- treatment
- ceramide levels
- ceramide
- Prior art date
Links
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 title 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 title 1
- 229940106189 ceramide Drugs 0.000 title 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 title 1
- 208000015181 infectious disease Diseases 0.000 title 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
- C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
- C12Y305/01023—Ceramidase (3.5.1.23)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dispersion Chemistry (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Otolaryngology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261654519P | 2012-06-01 | 2012-06-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2854910T true PT2854910T (pt) | 2020-05-06 |
Family
ID=49673925
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT137976353T PT2854910T (pt) | 2012-06-01 | 2013-05-31 | Níveis de ceramida no tratamento e prevenção de infeções |
Country Status (14)
| Country | Link |
|---|---|
| US (5) | US9492514B2 (pt) |
| EP (2) | EP3679923B1 (pt) |
| JP (5) | JP6369814B2 (pt) |
| CN (2) | CN104582770B (pt) |
| CA (1) | CA2874146C (pt) |
| DK (1) | DK2854910T3 (pt) |
| ES (2) | ES2786128T3 (pt) |
| HR (1) | HRP20200661T1 (pt) |
| HU (1) | HUE051020T2 (pt) |
| LT (1) | LT2854910T (pt) |
| PL (1) | PL2854910T3 (pt) |
| PT (1) | PT2854910T (pt) |
| SI (1) | SI2854910T1 (pt) |
| WO (1) | WO2013181530A1 (pt) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8889127B2 (en) | 2004-07-01 | 2014-11-18 | Icahn School Of Medicine At Mount Sinai | Targeted protein replacement for the treatment of lysosomal storage disorders |
| LT1993360T (lt) | 2005-12-28 | 2017-06-12 | Vertex Pharmaceuticals Incorporated | N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma |
| EP2753346B1 (en) | 2011-09-07 | 2020-04-22 | Mount Sinai School Of Medicine | Ceramidase and cell differentiation |
| PT2854910T (pt) | 2012-06-01 | 2020-05-06 | Yeda Res & Dev | Níveis de ceramida no tratamento e prevenção de infeções |
| US10023918B2 (en) | 2013-03-14 | 2018-07-17 | University Of Ottawa | Methods for the diagnosis and treatment of inflammatory bowel disease |
| MX390947B (es) * | 2013-03-14 | 2025-03-21 | Icahn School Med Mount Sinai | Composiciones terapéuticas de ceramidasa ácida y métodos para prepararlas y utilizarlas. |
| EP3201622A4 (en) | 2014-10-03 | 2018-05-30 | The University of Ottawa | Markers for inflammatory bowel disease |
| MX370450B (es) | 2014-10-07 | 2019-12-13 | Vertex Pharma | Co-cristales de moduladores de regulador de conductancia de transmembrana en fibrosis quistica. |
| JP7576293B2 (ja) * | 2017-01-13 | 2024-10-31 | アイカーン スクール オブ メディシン アット マウント サイナイ | ファーバー病を治療するための組成物及び方法 |
| WO2022190064A1 (en) * | 2021-03-12 | 2022-09-15 | Vexo Pharmaceuticals Dmcc | Methods for identifying subjects with betacoronavirus infections who are at risk of acute respiratory syndrome and methods for the treatment of same |
Family Cites Families (88)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
| CH585793A5 (pt) | 1974-02-01 | 1977-03-15 | Nestle Sa | |
| US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
| JPS5322158B2 (pt) | 1974-05-02 | 1978-07-06 | ||
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| IT1130242B (it) | 1980-02-01 | 1986-06-11 | Anic Spa | Procedimento per la produzione dell'enzima alfa-galattosidasi e per l'idrolisi del raffinosio mediante l'impiego dell'enzima stesso |
| US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
| US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| US5059421A (en) | 1985-07-26 | 1991-10-22 | The Liposome Company, Inc. | Preparation of targeted liposome systems of a defined size distribution |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| WO1990011353A1 (en) | 1989-03-24 | 1990-10-04 | Research Corporation Technologies, Inc. | Recombinant alpha-galactosidase, a therapy for fabry disease |
| US5401650A (en) | 1990-10-24 | 1995-03-28 | The Mount Sinai School Of Medicine Of The City University Of New York | Cloning and expression of biologically active α-galactosidase A |
| US5382524A (en) | 1990-10-24 | 1995-01-17 | The Mount Sinai School Of Medicine Of The City University Of New York | Cloning and expression of biologically active α-n-acetylgalactosaminidase |
| US5773278A (en) | 1991-05-03 | 1998-06-30 | Mount Sinai Medical Center | Acid sphingomyelinase gene |
| US5433946A (en) | 1991-10-11 | 1995-07-18 | Health Research Inc. | Synthesis and utilization of therapeutic agents for the treatment of lysosomal storage diseases |
| US5631237A (en) | 1992-12-22 | 1997-05-20 | Dzau; Victor J. | Method for producing in vivo delivery of therapeutic agents via liposomes |
| KR960700036A (ko) | 1992-12-30 | 1996-01-19 | 조오지 조 레비스 | 항골양 조성물(anticaries compositions) |
| JPH08512056A (ja) | 1993-06-30 | 1996-12-17 | ジェネンテク・インコーポレイテッド | リポソームの製造法 |
| US5885613A (en) | 1994-09-30 | 1999-03-23 | The University Of British Columbia | Bilayer stabilizing components and their use in forming programmable fusogenic liposomes |
| US5997861A (en) | 1994-10-31 | 1999-12-07 | Burstein Laboratories, Inc. | Antiviral supramolecules containing target-binding molecules and therapeutic molecules bound to spectrin |
| US5817789A (en) | 1995-06-06 | 1998-10-06 | Transkaryotic Therapies, Inc. | Chimeric proteins for use in transport of a selected substance into cells |
| US5643599A (en) | 1995-06-07 | 1997-07-01 | President And Fellows Of Harvard College | Intracellular delivery of macromolecules |
| US6118045A (en) | 1995-08-02 | 2000-09-12 | Pharming B.V. | Lysosomal proteins produced in the milk of transgenic animals |
| US6884435B1 (en) | 1997-01-30 | 2005-04-26 | Chiron Corporation | Microparticles with adsorbent surfaces, methods of making same, and uses thereof |
| IL135578A0 (en) | 1997-10-29 | 2001-05-20 | Genzyme Corp | Compositions and methods for treating lysosomal storage disease |
| AU753303B2 (en) | 1998-03-10 | 2002-10-17 | Trustees Of The University Of Pennsylvania, The | Enhancement of intracellular delivery and tissue targeting of drugs and genes |
| US6274597B1 (en) | 1998-06-01 | 2001-08-14 | Mount Sinai School Of Medicine Of New York University | Method of enhancing lysosomal α-Galactosidase A |
| US7018628B1 (en) | 1998-07-24 | 2006-03-28 | Aventis Pharma S.A. | Vectors derived from baculovirus and use for transferring nucleic acids into nerve cells of vertebrates |
| US6258581B1 (en) | 1998-08-20 | 2001-07-10 | Takara Shuzo Co., Ltd. | Ceramidase gene |
| GB9909064D0 (en) | 1999-04-20 | 1999-06-16 | Oxford Glycosciences Uk Ltd | Therapies |
| US6730297B1 (en) | 1999-05-28 | 2004-05-04 | Chiron Corporation | Use of recombinant gene delivery vectors for treating or preventing lysosomal storage disorders |
| US7927587B2 (en) | 1999-08-05 | 2011-04-19 | Regents Of The University Of Minnesota | MAPC administration for the treatment of lysosomal storage disorders |
| US6767741B1 (en) | 1999-08-27 | 2004-07-27 | Invitrogen Corporation | Metal binding compounds and their use in cell culture medium compositions |
| US6537785B1 (en) | 1999-09-14 | 2003-03-25 | Genzyme Glycobiology Research Institute, Inc. | Methods of treating lysosomal storage diseases |
| IL149093A0 (en) | 1999-10-13 | 2002-11-10 | Yeda Res & Dev | Short segments of dap-kinase |
| US6350768B1 (en) | 1999-11-24 | 2002-02-26 | Aventis Pharma S.A. | Combination of riluzole and of gabapentin and its use as a medicament |
| US7850984B2 (en) | 2000-02-15 | 2010-12-14 | The General Hospital Corporation | Protection of the female reproductive system from natural and artificial insults |
| IL152110A0 (en) | 2000-04-06 | 2003-07-31 | Exegenics Inc | Expression system for efficiently producing clinically effective lysosomal enzymes (glucocerebrosidase) |
| US20040204379A1 (en) | 2000-06-19 | 2004-10-14 | Cheng Seng H. | Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
| AU2002239721C1 (en) | 2000-12-22 | 2008-04-24 | Medlyte, Inc. | Compositions and methods for the treatment and prevention of cardiovascular diseases and disorders, and for identifying agents therapeutic therefor |
| US20020142299A1 (en) | 2001-01-09 | 2002-10-03 | Davidson Beverly L. | PTD-modified proteins |
| EP1234816B1 (de) | 2001-02-23 | 2004-06-30 | Biofrontera Pharmaceuticals GmbH | Scyphostatin-Analoga als SMase-Inhibitoren |
| WO2002087510A2 (en) | 2001-04-30 | 2002-11-07 | Symbiontics, Inc. | Subcellular targeting of therapeutic proteins |
| US7232670B2 (en) | 2001-09-28 | 2007-06-19 | St. Jude Children's Research Hospital | Targeting proteins to cells expressing mannose receptors via expression in insect cells |
| CA2473360A1 (en) | 2002-01-25 | 2003-08-07 | Genzyme Corporation | Serum-free media for chondrocytes and methods of use thereof |
| WO2003086452A2 (en) | 2002-04-05 | 2003-10-23 | Genzyme Corporation | Methods of enhancing lysosomal storage disease therapy |
| DE10239531A1 (de) * | 2002-08-23 | 2004-03-04 | Gulbins, Erich, Prof. Dr. | Prophylaxe und Therapie von Infektionserkrankungen |
| EP1431399A1 (en) | 2002-12-20 | 2004-06-23 | Clinigenetics | Methods and composition for identifying therapeutic agents of atherosclerotic plaque lesions |
| ES2371913T3 (es) | 2003-01-22 | 2012-01-11 | Duke University | Constructos mejorados para expresar polipéptidos lisosomales. |
| US20050026823A1 (en) | 2003-06-20 | 2005-02-03 | Biomarin Pharmaceutical Inc. | Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues |
| NZ544977A (en) | 2003-07-17 | 2009-07-31 | Pacific Edge Biotechnology Ltd | Cystatin SN ("CST1") as a marker for detection of gastric cancer |
| US7919094B2 (en) | 2004-06-10 | 2011-04-05 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| US8889127B2 (en) | 2004-07-01 | 2014-11-18 | Icahn School Of Medicine At Mount Sinai | Targeted protein replacement for the treatment of lysosomal storage disorders |
| US8017394B2 (en) | 2004-10-01 | 2011-09-13 | Isto Technologies, Inc. | Method for chondrocyte expansion with phenotype retention |
| US7273756B2 (en) | 2004-10-01 | 2007-09-25 | Isto Technologies, Inc. | Method for chondrocyte expansion with phenotype retention |
| EP1814841A4 (en) | 2004-10-29 | 2011-03-16 | Musc Found For Res Dev | CERAMIDES AND LIGANDS OF SIGNALING APOPTOSIS |
| EP1877416A4 (en) | 2005-04-19 | 2010-02-10 | Vermillion Inc | SAPOSIN D AND FAM3C ARE BIOLOGICAL MARKERS FOR ALZHEIMER DISEASE |
| CN101282733A (zh) * | 2005-08-03 | 2008-10-08 | 莫里亚生物制药公司 | 脂质结合物在囊性纤维化病中的用途及其应用 |
| US20070162992A1 (en) | 2006-01-09 | 2007-07-12 | Mcgill University | Metabolomic determination in assisted reproductive technology |
| CA2640614A1 (en) | 2006-01-27 | 2007-08-09 | Eastern Virginia Medical School | Proteomic fingerprinting of human ivf-derived embryos: identification of biomarkers of developmental potential |
| WO2007095688A1 (en) | 2006-02-23 | 2007-08-30 | The Australian National University | Methods for increasing the number of circulating cells |
| JP2009538276A (ja) * | 2006-04-24 | 2009-11-05 | アカデミッシュ メディシュ セントラム | 嚢胞性線維症の改良型治療 |
| WO2007136635A1 (en) * | 2006-05-16 | 2007-11-29 | Musc Foundation For Research Development | Enhancement of radiation therapy and/or chemotherapy with acid ceramidase modulators |
| EP2924440A3 (en) | 2006-06-07 | 2016-03-09 | Health Diagnostic Laboratory, Inc. | Markers associated with arteriovascular events and methods of use thereof |
| MX2008016429A (es) | 2006-06-20 | 2009-03-20 | Genzyme Corp | Medios de suero y sus usos para expansion de condrocitos. |
| JP5431961B2 (ja) * | 2007-01-05 | 2014-03-05 | マウント シナイ スクール オブ メディシン | 酸性セラミダーゼおよび細胞の生存を促進する方法 |
| ATE541211T1 (de) | 2007-04-06 | 2012-01-15 | Genzyme Corp | Verfahren zur beurteilung von zellen und zellkulturen |
| US8956825B2 (en) | 2007-05-24 | 2015-02-17 | The United States Of America As Represented By The Department Of Veterans Affairs | Intranuclear protein transduction through a nucleoside salvage pathway |
| CA2689027C (en) | 2007-05-31 | 2016-07-19 | Deirdre Roma Coombe | Sulphated xylans for treatment or prophylaxis of respiratory diseases |
| FR2924946B1 (fr) | 2007-12-18 | 2010-02-26 | Oreal | Utilisation cosmetique de proteines de type ceramidase acide |
| DE102007063535A1 (de) * | 2007-12-21 | 2009-06-25 | Cycnad Gmbh & Co. Kg | Pharmazeutische Zusammensetzung zur Prophylaxe und/oder symptomatischen Behandlung von zystischer Fibrose |
| AU2009262670B2 (en) | 2008-06-26 | 2013-06-20 | Zevra Denmark A/S | Use of Hsp70 as a regulator of enzymatic activity |
| US20100068302A1 (en) | 2008-09-17 | 2010-03-18 | Traslational Cancer Drugs Pharma, S.L. | Methods and compositions for the treatment of cancer |
| JP5721631B2 (ja) * | 2008-11-06 | 2015-05-20 | ムスク ファウンデーション フォー リサーチ デベロップメント | 酸性セラミダーゼのリソソーム親和性阻害剤 |
| WO2010127355A1 (en) | 2009-05-01 | 2010-11-04 | Mount Sinai School Of Medicine | Method to determine embryo and oocyte quality based on ceramidase |
| HRP20191385T1 (hr) | 2009-08-28 | 2019-11-01 | Icahn School Med Mount Sinai | Povećavanje doze terapije zamjene enzima za liječenje deficijencije kisele sfingomijelinaze |
| DK2490533T3 (en) | 2009-10-19 | 2015-12-07 | Amicus Therapeutics Inc | NOVEL COMPOSITIONS FOR PREVENTION AND / OR TREATMENT OF Lysosomal Storage DISEASES |
| PH12015502514B1 (en) | 2009-11-27 | 2022-07-29 | Genzyme Corp | An amorphous and crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase |
| WO2012051415A2 (en) * | 2010-10-13 | 2012-04-19 | Mount Sinai School Of Medicine | Inhibitors of acid ceramidase and uses thereof in cancer and other disease treatment therapies |
| WO2013101276A2 (en) | 2011-04-01 | 2013-07-04 | Mount Sinai School Of Medicine | Diagnosis and detection of disease conditions modulated by activation of the sphingolipid pathway |
| AU2012253595B2 (en) | 2011-05-10 | 2016-10-20 | Advanced Liquid Logic, Inc. | Enzyme concentration and assays |
| JP6175431B2 (ja) | 2011-06-20 | 2017-08-02 | アイカーン スクール オブ メディシン アット マウント サイナイ | ムコ多糖症およびその他のリソソーム障害に対する抗ｔｎｆ療法 |
| EP2753346B1 (en) | 2011-09-07 | 2020-04-22 | Mount Sinai School Of Medicine | Ceramidase and cell differentiation |
| PT2854910T (pt) | 2012-06-01 | 2020-05-06 | Yeda Res & Dev | Níveis de ceramida no tratamento e prevenção de infeções |
| MX390947B (es) | 2013-03-14 | 2025-03-21 | Icahn School Med Mount Sinai | Composiciones terapéuticas de ceramidasa ácida y métodos para prepararlas y utilizarlas. |
-
2013
- 2013-05-31 PT PT137976353T patent/PT2854910T/pt unknown
- 2013-05-31 JP JP2015515238A patent/JP6369814B2/ja active Active
- 2013-05-31 ES ES13797635T patent/ES2786128T3/es active Active
- 2013-05-31 CA CA2874146A patent/CA2874146C/en active Active
- 2013-05-31 EP EP20161022.7A patent/EP3679923B1/en active Active
- 2013-05-31 ES ES20161022T patent/ES2897825T3/es active Active
- 2013-05-31 HR HRP20200661TT patent/HRP20200661T1/hr unknown
- 2013-05-31 HU HUE13797635A patent/HUE051020T2/hu unknown
- 2013-05-31 SI SI201331715T patent/SI2854910T1/sl unknown
- 2013-05-31 EP EP13797635.3A patent/EP2854910B1/en active Active
- 2013-05-31 WO PCT/US2013/043608 patent/WO2013181530A1/en active Application Filing
- 2013-05-31 CN CN201380031825.3A patent/CN104582770B/zh active Active
- 2013-05-31 CN CN201811635845.2A patent/CN109529028A/zh active Pending
- 2013-05-31 DK DK13797635.3T patent/DK2854910T3/da active
- 2013-05-31 US US14/404,881 patent/US9492514B2/en active Active
- 2013-05-31 LT LTEP13797635.3T patent/LT2854910T/lt unknown
- 2013-05-31 PL PL13797635T patent/PL2854910T3/pl unknown
-
2016
- 2016-10-05 US US15/286,327 patent/US10159724B2/en active Active
-
2018
- 2018-07-02 JP JP2018125882A patent/JP6639574B2/ja active Active
- 2018-11-15 US US16/192,241 patent/US20190151424A1/en not_active Abandoned
-
2019
- 2019-12-24 JP JP2019232581A patent/JP2020050668A/ja not_active Withdrawn
-
2021
- 2021-08-09 US US17/397,298 patent/US20220202919A1/en not_active Abandoned
-
2022
- 2022-12-14 JP JP2022199280A patent/JP2023021305A/ja active Pending
-
2024
- 2024-07-18 US US18/777,129 patent/US20250186565A1/en active Pending
-
2025
- 2025-04-02 JP JP2025060890A patent/JP2025102904A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2015518054A (ja) | 2015-06-25 |
| JP6639574B2 (ja) | 2020-02-05 |
| US20220202919A1 (en) | 2022-06-30 |
| HRP20200661T1 (hr) | 2020-10-30 |
| US20150125439A1 (en) | 2015-05-07 |
| ES2786128T3 (es) | 2020-10-08 |
| PL2854910T3 (pl) | 2020-07-27 |
| CA2874146A1 (en) | 2013-12-05 |
| US20170020998A1 (en) | 2017-01-26 |
| US20190151424A1 (en) | 2019-05-23 |
| DK2854910T3 (da) | 2020-05-04 |
| ES2897825T3 (es) | 2022-03-02 |
| US10159724B2 (en) | 2018-12-25 |
| EP2854910B1 (en) | 2020-04-15 |
| CN104582770A (zh) | 2015-04-29 |
| CN104582770B (zh) | 2019-01-29 |
| CN109529028A (zh) | 2019-03-29 |
| US20250186565A1 (en) | 2025-06-12 |
| EP2854910A4 (en) | 2016-02-24 |
| EP3679923A1 (en) | 2020-07-15 |
| EP2854910A1 (en) | 2015-04-08 |
| US9492514B2 (en) | 2016-11-15 |
| JP2018162303A (ja) | 2018-10-18 |
| JP2023021305A (ja) | 2023-02-10 |
| JP2020050668A (ja) | 2020-04-02 |
| EP3679923B1 (en) | 2021-08-04 |
| CA2874146C (en) | 2023-03-21 |
| JP2025102904A (ja) | 2025-07-08 |
| LT2854910T (lt) | 2020-05-25 |
| SI2854910T1 (sl) | 2020-09-30 |
| JP6369814B2 (ja) | 2018-08-08 |
| WO2013181530A1 (en) | 2013-12-05 |
| HUE051020T2 (hu) | 2021-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL266582A (en) | Preparations and methods for the treatment of hemoglobin diseases | |
| SI2854910T1 (sl) | Nivoji ceramida pri zdravljenju in preprečevanju okužb | |
| EP2847152A4 (en) | COMPOSITIONS AND METHOD FOR THE TREATMENT OF METABOLIC SYNDROME | |
| GB201217296D0 (en) | Method of treatment and/or prevention | |
| ZA201408055B (en) | Compositions and methods for the treatment of local pain | |
| SG11201504542PA (en) | Probiotic strains for the treatment and/or prevention of diarrhœa | |
| IL238126A0 (en) | Compositions for the treatment and prevention of obesity | |
| ZA201501494B (en) | Sirna and their use in methods and compositions for the treatment and/or prevention of eye conditions | |
| IL233875A (en) | Preparation and use for the treatment of anal fissures | |
| ZA201502181B (en) | Sirna and their use in methods and compositions for the treatment and/or prevention of eye conditions | |
| ZA201503266B (en) | Pyidone derivatives and uses thereof in the treatment of tuberculosis | |
| PT2862576T (pt) | Microrganismos e composições que os compreendem para utilização no tratamento ou prevenção de mastite | |
| SG11201500838UA (en) | Eprotirome for use in the prevention and/or treatment of hair disorders and compositions thereof | |
| ZA201408053B (en) | Compositions and methods for the treatment of metabolic syndrome | |
| GB2510477B (en) | Formulations for use in the treatment of chronic fatigue and associated conditions, etc | |
| HUE036306T2 (hu) | Odiparcil alkalmazása mukopoliszacharidózis kezelésében | |
| SI2771016T1 (sl) | Primicin in njegove komponente za uporabo pri zdravljenju ali preventivi okužb povzročenimi s specifičnimi patogeni | |
| PT2389936E (pt) | Aminaftona para utilização no tratamento e/ou prevenção de enxaqueca | |
| GB201206806D0 (en) | Device for the prevention and cure of motion sickness |